Bausch Health Companies (BHC)
NYSE:BHC
Want to see BHC full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.01Last Year’s EPS
1.06Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong operational and financial execution with broad revenue and adjusted EBITDA growth across the company (notably Salix and Solta), improved margins, healthy cash flow and net debt reduction. Management reaffirmed guidance and highlighted strategic R&D progress (larsucosterol Phase III) and AI-driven commercial/R&D productivity gains. Offsetting risks include a decline in the Diversified segment, Canadian branded generic pressure, acquisition-related inventory costs at Solta, litigation-related cash outflows and policy/tariff and potential exclusivity risks for Xifaxan that could affect future cash flow. On balance, the positive operational momentum, sizable organic and reported growth, margin expansion and strong cash generation outweigh the headwinds described.Company Guidance
Consistent Top-Line and EBITDA Growth
Bausch Health (excluding Bausch & Lomb) reported revenue of $1.280 billion, up 14% reported and 9% organic year-over-year, and adjusted EBITDA of $673 million, up 17% year-over-year. The company has now delivered 12 consecutive quarters of year-over-year growth in both revenue and adjusted EBITDA for the Bausch Health segment (ex-B&L).
Strong Consolidated Financial Results
Consolidated revenue was $2.524 billion, up 12% reported (7% organic). Consolidated adjusted EBITDA rose to $837 million, a $176 million increase or 27% year-over-year. Adjusted gross margin improved to 70.9%, up 100 basis points.
Healthy Cash Flow and Debt Reduction
Adjusted operating cash flow was $374 million consolidated and $319 million for Bausch Health (ex-B&L), nearly $200 million higher than Q1 2025 for the segment. Net debt (ex-B&L) decreased by approximately $150 million in the quarter despite approximately $160 million of litigation-related outflows.
Salix and Xifaxan Performance
Salix revenues were $639 million, up 18% reported (+$97 million). Xifaxan grew 21% year-over-year with total scripts in commercial and Medicare channels up 6% and new-to-brand scripts up 3%. Management cited strong physician engagement and improved patient access as drivers.
Exceptional Solta Growth, Especially in China
Solta Medical revenues were $171 million, up 51% reported and 19% organic; segment profit grew 42% reported. China revenues grew 193% year-over-year and volume up 52% (integration of Shibo distributor contributed to pricing and volume gains). China is now Solta's largest geography.
Geographic and Product Momentum
EMEA achieved its 13th consecutive quarter of organic revenue growth (EMEA organic +3%). Solta also showed broad momentum in South Korea (+17%) and positive growth in the U.S., EMEA and Canada (high single to low double-digit reported growth outside APAC).
Reaffirmed 2026 Guidance
Company reaffirmed full-year 2026 guidance (Bausch Health ex-B&L): revenue $5.250B–$5.400B (midpoint ≈ +3% YoY), adjusted EBITDA $2.875B–$2.950B (midpoint ≈ +4% YoY) and adjusted operating cash flow $1.200B–$1.275B (midpoint ≈ +4% YoY). Guidance incorporates anticipated new tariffs effective Sept 29, 2026.
Progress in R&D and Targeted Pipeline Development
Advancing larsucosterol into a U.S.-only Phase III for alcohol-associated hepatitis with design changes (U.S.-focused enrollment, randomization within 9 days of presentation and larger, well-powered trial). Company is prioritizing indications across acquired and in-house assets and applying AI to accelerate R&D and clinical operations.
AI-Enabled Commercial and R&D Productivity Gains
Company reported a 20% surge in sales productivity from AI-enabled customer insights (initially for Xifaxan) and early AI programs for Relistor showing ~20%+ lift in new prescriptions for targeted HCP cohorts. AI also used to speed site selection, recruitment and pharmacovigilance workflows.
BHC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BHC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $5.59 | $5.72 | +2.33% |
Feb 18, 2026 | $6.19 | $5.93 | -4.20% |
Oct 29, 2025 | $5.90 | $6.61 | +12.03% |
Jul 30, 2025 | $6.39 | $5.89 | -7.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bausch Health Companies (BHC) report earnings?
Bausch Health Companies (BHC) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Bausch Health Companies (BHC) earnings time?
Bausch Health Companies (BHC) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BHC EPS forecast?
BHC EPS forecast for the fiscal quarter 2026 (Q2) is 1.01.